Get the Stockscreener App
0.58
3.57%
0.02
After Hours:
.58
Xtant Medical Holdings Inc stock is traded at $0.58, with a volume of 103.30K.
It is up +3.57% in the last 24 hours and up +17.86% over the past month.
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as could be used in conjunction with a hardware plate system. The company also provides OsteoSTX for posterolateral spine surgery applications, including scoliosis procedures; and 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers various products to treat a range of spinal and sacroiliac conditions, including trauma, degeneration, deformity, and tumor. Xtant Medical Holdings, Inc. markets its products through direct sales, consignment agents, reseller distributors, private label distributors, and technology licensees. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.
See More
Previous Close:
$0.56
Open:
$0.579
24h Volume:
103.30K
Relative Volume:
0.70
Market Cap:
$81.24M
Revenue:
$133.93M
Net Income/Loss:
$4.97M
P/E Ratio:
17.37
EPS:
0.0334
Net Cash Flow:
$10.12M
1W Performance:
+4.92%
1M Performance:
+17.86%
6M Performance:
-27.32%
1Y Performance:
+15.45%
1-Day Range:
$0.5702
$0.5923
1-Week Range:
$0.516
$0.5923
52-Week Range:
$0.438
$0.95
Xtant Medical Holdings Inc Stock (XTNT) Company Profile
Name
Xtant Medical Holdings Inc
Sector
Industry
Phone
406-388-0480
Address
664 Cruiser Lane, Belgrade, MT
Compare XTNT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XTNT
Xtant Medical Holdings Inc
|
0.58 | 78.44M | 133.93M | 4.97M | 10.12M | 0.0334 |
ABT
Abbott Laboratories
|
87.17 | 152.48B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 111.40B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 100.53B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 84.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.91 | 48.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
Xtant Medical Holdings Inc Stock (XTNT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-23 | Initiated | BTIG Research | Buy |
| Nov-15-18 | Reiterated | Maxim Group | Buy |
| Feb-14-18 | Reiterated | Maxim Group | Buy |
Xtant Medical Holdings Inc Stock (XTNT) Latest News
MSN Money - MSN
3 Promising Penny Stocks With Market Caps Under $200M - simplywall.st
Xtant Medical shares drop nearly 5% as weak 2026 outlook overshadows Q4 beat - MSN
Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Down 67.8% in April - MarketBeat
Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results (PR Newswire) - Aktiellt
Xtant (XTNT) Stock Prediction | Xtant Medical posts 100% EPS surprise, beats loss estimatesTrending Buy Opportunities - Cổng thông tin điện tử tỉnh Lào Cai
Xtant (XTNT) Stock: Risks and Growth Potential | Q4 2025: Earnings Beat EstimatesOperating Income - Cổng thông tin điện tử tỉnh Lào Cai
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Xtant Medical (XTNT): Buy Rating and Growth Prospects Highlighted - GuruFocus
Xtant Medical Holdings, Inc. (XTNT) - Minichart
Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Large Growth in Short Interest - MarketBeat
Xtant Medical acquires exclusive U.S. rights to HEMOBLAST Bellows By Investing.com - Investing.com Australia
Xtant Medical Holdings, Inc. and Dilon Technologies, Inc Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows Product - marketscreener.com
Xtant Medical Secures Exclusive U.S. Distribution Rights for Dilon’s HEMOBLAST Bellows Hemostatic Product and Expands Sales Team - Minichart
Xtant Medical Expands Portfolio with HEMOBLAST Distribution Deal - TipRanks
Xtant Medical acquires exclusive U.S. rights to HEMOBLAST Bellows - Investing.com
Xtant Medical (XTNT) pays $5M for exclusive U.S. HEMOBLAST rights, adds 20 sales staff - Stock Titan
Xtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows Product - PR Newswire
Breakout Move: Can Xtant Medical Holdings Inc outperform under higher oil pricesTrade Analysis Report & High Win Rate Trade Alerts - baoquankhu1.vn
Sentiment Watch: Is Xtant Medical Holdings Inc stock overvalued or fairly priced2026 EndofYear Setup & Smart Swing Trading Techniques - baoquankhu1.vn
Meme Stocks: Can Xtant Medical Holdings Inc deliver consistent dividends2026 Stock Rankings & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Xtant Medical and Montana Governor's Office of Community Service Announce Support for "Threshold of Life" Memorial - Financial Times
Craig-Hallum Maintains Buy on Xtant Medical Holdings, Inc. (XTNT) March 2026 - Meyka
XTNT PE Ratio & Valuation, Is XTNT Overvalued - Intellectia AI
XTNT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Craig-Hallum Maintains Buy on Xtant Medical (XTNT) March 18, 2026 - Meyka
Xtant Medical Earnings Call Highlights Profitability Turnaround - The Globe and Mail
Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results - Orthopedics This Week
Xtant Medical (NYSEAMERICAN:XTNT) Issues Quarterly Earnings Results - MarketBeat
Xtant Medical Holdings, Inc. (AMEX:XTNT) Q4 2025 Earnings Call Transcript - Insider Monkey
Xtant Medical Achieves Profitability and 14% Revenue Growth in 2025, Provides 2026 Outlook After Strategic Divestiture - Minichart
Xtant Medical (NYSEAMERICAN:XTNT) Price Target Cut to $1.00 by Analysts at BTIG Research - Defense World
Xtant outlines $95M-$99M 2026 revenue outlook as Companion Spine divestiture and Q-code license revenue roll off - msn.com
Latest XTNT NewsXtant Medical Announces Debt Restructuring - Stock Titan
Xtant Medical Holdings, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
XTNT Stock Update: Analyst Lowers Price Target Amid Buy Rating | - GuruFocus
Xtant Medical Q4 2025 Earnings Call Transcript - MarketBeat
Xtant Medical Holdings, Inc. 2025 Annual Report: Orthobiologics, Spinal Implants, and Company Overview - Minichart
Xtant Medical Holdings, Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
XTNT: 2025 saw double-digit revenue growth and profitability, with 2026 focused on core biologics acceleration - TradingView — Track All Markets
American Shared Hospital Services (AMS) Reports Q4 Earnings - news.alphastreet.com
Xtant Medical Holdings, Inc. (XTNT) Reports In-Line Q4 Earnings - AlphaStreet
Xtant Medical Holdings 2025 10-K: $133.9M Revenue, $0.03 Diluted EPS - TradingView
XTNT: 2025 net income of $5.0M driven by one-time gains; 2026 outlook pressured by lost license revenue - TradingView — Track All Markets
Xtant Medical (NYSE: XTNT) sheds one-time 2025 gains, sells Coflex/CoFix assets - Stock Titan
Xtant Medical Holdings reports FY2025 revenue $133.9M, net income $5.0M and adjusted EBITDA $16.3M - TradingView
XTNT: 2025 saw 14% revenue growth, profitability, and a strategic shift to core biologics - TradingView — Track All Markets
Form 8-KCurrent report - ADVFN
Xtant Medical Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Xtant Medical Holdings Inc Stock (XTNT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):